JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias
Las Palmas de Gran Canaria, EspañaPublications in collaboration with researchers from Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias (7)
2021
-
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999
2020
-
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270
2018
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
2017
-
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2016
-
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302
2015
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43